Which Is It: ADHD, Bipolar Disorder, Or PTSD?
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
First Episode Psychosis an Information Guide Revised Edition
First episode psychosis An information guide revised edition Sarah Bromley, OT Reg (Ont) Monica Choi, MD, FRCPC Sabiha Faruqui, MSc (OT) i First episode psychosis An information guide Sarah Bromley, OT Reg (Ont) Monica Choi, MD, FRCPC Sabiha Faruqui, MSc (OT) A Pan American Health Organization / World Health Organization Collaborating Centre ii Library and Archives Canada Cataloguing in Publication Bromley, Sarah, 1969-, author First episode psychosis : an information guide : a guide for people with psychosis and their families / Sarah Bromley, OT Reg (Ont), Monica Choi, MD, Sabiha Faruqui, MSc (OT). -- Revised edition. Revised edition of: First episode psychosis / Donna Czuchta, Kathryn Ryan. 1999. Includes bibliographical references. Issued in print and electronic formats. ISBN 978-1-77052-595-5 (PRINT).--ISBN 978-1-77052-596-2 (PDF).-- ISBN 978-1-77052-597-9 (HTML).--ISBN 978-1-77052-598-6 (ePUB).-- ISBN 978-1-77114-224-3 (Kindle) 1. Psychoses--Popular works. I. Choi, Monica Arrina, 1978-, author II. Faruqui, Sabiha, 1983-, author III. Centre for Addiction and Mental Health, issuing body IV. Title. RC512.B76 2015 616.89 C2015-901241-4 C2015-901242-2 Printed in Canada Copyright © 1999, 2007, 2015 Centre for Addiction and Mental Health No part of this work may be reproduced or transmitted in any form or by any means electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system without written permission from the publisher—except for a brief quotation (not to exceed 200 words) in a review or professional work. This publication may be available in other formats. For information about alterna- tive formats or other CAMH publications, or to place an order, please contact Sales and Distribution: Toll-free: 1 800 661-1111 Toronto: 416 595-6059 E-mail: [email protected] Online store: http://store.camh.ca Website: www.camh.ca Disponible en français sous le titre : Le premier épisode psychotique : Guide pour les personnes atteintes de psychose et leur famille This guide was produced by CAMH Publications. -
Is Your Depressed Patient Bipolar?
J Am Board Fam Pract: first published as 10.3122/jabfm.18.4.271 on 29 June 2005. Downloaded from EVIDENCE-BASED CLINICAL MEDICINE Is Your Depressed Patient Bipolar? Neil S. Kaye, MD, DFAPA Accurate diagnosis of mood disorders is critical for treatment to be effective. Distinguishing between major depression and bipolar disorders, especially the depressed phase of a bipolar disorder, is essen- tial, because they differ substantially in their genetics, clinical course, outcomes, prognosis, and treat- ment. In current practice, bipolar disorders, especially bipolar II disorder, are underdiagnosed. Misdi- agnosing bipolar disorders deprives patients of timely and potentially lifesaving treatment, particularly considering the development of newer and possibly more effective medications for both depressive fea- tures and the maintenance treatment (prevention of recurrence/relapse). This article focuses specifi- cally on how to recognize the identifying features suggestive of a bipolar disorder in patients who present with depressive symptoms or who have previously been diagnosed with major depression or dysthymia. This task is not especially time-consuming, and the interested primary care or family physi- cian can easily perform this assessment. Tools to assist the physician in daily practice with the evalua- tion and recognition of bipolar disorders and bipolar depression are presented and discussed. (J Am Board Fam Pract 2005;18:271–81.) Studies have demonstrated that a large proportion orders than in major depression, and the psychiat- of patients in primary care settings have both med- ric treatments of the 2 disorders are distinctly dif- ical and psychiatric diagnoses and require dual ferent.3–5 Whereas antidepressants are the treatment.1 It is thus the responsibility of the pri- treatment of choice for major depression, current mary care physician, in many instances, to correctly guidelines recommend that antidepressants not be diagnose mental illnesses and to treat or make ap- used in the absence of mood stabilizers in patients propriate referrals. -
Types of Bipolar Disorder Toms Are Evident
MOOD DISORDERS ASSOCIATION OF BRITISH COLUmbIA T Y P E S O F b i p o l a r d i s o r d e r Bipolar disorder is a class of mood disorders that is marked by dramatic changes in mood, energy and behaviour. The key characteristic is that people with bipolar disorder alternate be- tween episodes of mania (extreme elevated mood) and depression (extreme sadness). These episodes can last from hours to months. The mood distur- bances are severe enough to cause marked impairment in the person’s func- tioning. The experience of mania is not pleasant and can be very frightening to The Diagnotistic Statisti- the person. It can lead to impulsive behaviour that has serious consequences cal Manual (DSM- IV-TR) is a for the person and their family. A depressive episode makes it difficult or -im manual used by doctors to possible for a person to function in their daily life. determine the specific type of bipolar disorder. People with bipolar disorder vary in how often they experience an episode of either mania or depression. Mood changes with bipolar disorder typically occur gradually. For some individuals there may be periods of wellness between the different mood episodes. Some people may also experience multiple episodes within a 12 month period, a week, or even a single day (referred to as “rapid cycling”). The severity of the mood can also range from mild to severe. Establishing the particular type of bipolar disorder can greatly aid in determin- ing the best type of treatment to manage the symptoms. -
Pharmacogenomic Characterization in Bipolar Spectrum Disorders
pharmaceutics Review Pharmacogenomic Characterization in Bipolar Spectrum Disorders Stefano Fortinguerra 1,2 , Vincenzo Sorrenti 1,2,3 , Pietro Giusti 2, Morena Zusso 2 and Alessandro Buriani 1,2,* 1 Maria Paola Belloni Center for Personalized Medicine, Data Medica Group (Synlab Limited), 35131 Padova, Italy; [email protected] (S.F.); [email protected] (V.S.) 2 Department of Pharmaceutical & Pharmacological Sciences, University of Padova, 35131 Padova, Italy; [email protected] (P.G.); [email protected] (M.Z.) 3 Bendessere™ Study Center, Solgar Italia Multinutrient S.p.A., 35131 Padova, Italy * Correspondence: [email protected] Received: 25 November 2019; Accepted: 19 December 2019; Published: 21 December 2019 Abstract: The holistic approach of personalized medicine, merging clinical and molecular characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily spreading in clinical practice. Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression. Patients misdiagnosed as depressed are often initially prescribed serotonergic antidepressants, a treatment that can exacerbate a previously unrecognized bipolar condition. Thanks to the use of the patient’s genomic profile, it is possible to recognize such risk and at the same time characterize specific genetic assets specifically associated with bipolar spectrum disorder, as well as with the individual response to the various therapeutic options. This provides the basis for molecular diagnosis and the definition of pharmacogenomic profiles, thus guiding therapeutic choices and allowing a safer and more effective use of psychotropic drugs. Here, we report the pharmacogenomics state of the art in bipolar disorders and suggest an algorithm for therapeutic regimen choice. -
Bionomics to Trial Drug Against Post-Traumatic Stress Disorder
ABN 53 075 582 740 ASX ANNOUNCEMENT 30 June 2016 BIONOMICS TO TRIAL DRUG AGAINST POST-TRAUMATIC STRESS DISORDER Trial to examine effects of Bionomics’ drug candidate BNC210 on PTSD No current effective treatments for PTSD 5-10% of population will suffer PTSD at some point ADELAIDE, Australia, 30 June 2016: Bionomics Limited (ASX:BNO; OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system and cancer, has initiated a Phase II clinical trial with its drug candidate BNC210 in adults suffering Post- Traumatic Stress Disorder (PTSD). The study’s primary objective is to determine whether BNC210 causes a decrease in symptoms of PTSD as measured by the globally-accepted Clinician-Administered PTSD Scale (CAPS-5). Secondary objectives include the determination of the effects of BNC210 on anxiety, depression, quality of life, and safety. This clinical study will recruit 160 subjects with PTSD at 8-10 clinical research centres throughout Australia and New Zealand. The study is a randomized, double-blind, placebo-controlled design with subjects to be treated over 12 weeks with BNC210 or placebo. The Principal Investigator is Professor Jayashri Kulkarni from the Monash Alfred Psychiatry Research Centre in Melbourne, Australia. PTSD is very common and its societal and economic burden extremely heavy. It is estimated that 5-10% of the general population will suffer from PTSD at some point in their lives. There is a need for further and improved pharmacotherapy options for people with PTSD. Currently, only two drugs, the antidepressants paroxetine and sertraline, are approved for the treatment of PTSD. -
Specificity of Psychosis, Mania and Major Depression in A
Molecular Psychiatry (2014) 19, 209–213 & 2014 Macmillan Publishers Limited All rights reserved 1359-4184/14 www.nature.com/mp ORIGINAL ARTICLE Specificity of psychosis, mania and major depression in a contemporary family study CL Vandeleur1, KR Merikangas2, M-PF Strippoli1, E Castelao1 and M Preisig1 There has been increasing attention to the subgroups of mood disorders and their boundaries with other mental disorders, particularly psychoses. The goals of the present paper were (1) to assess the familial aggregation and co-aggregation patterns of the full spectrum of mood disorders (that is, bipolar, schizoaffective (SAF), major depression) based on contemporary diagnostic criteria; and (2) to evaluate the familial specificity of the major subgroups of mood disorders, including psychotic, manic and major depressive episodes (MDEs). The sample included 293 patients with a lifetime diagnosis of SAF disorder, bipolar disorder and major depressive disorder (MDD), 110 orthopedic controls, and 1734 adult first-degree relatives. The diagnostic assignment was based on all available information, including direct diagnostic interviews, family history reports and medical records. Our findings revealed specificity of the familial aggregation of psychosis (odds ratio (OR) ¼ 2.9, confidence interval (CI): 1.1–7.7), mania (OR ¼ 6.4, CI: 2.2–18.7) and MDEs (OR ¼ 2.0, CI: 1.5–2.7) but not hypomania (OR ¼ 1.3, CI: 0.5–3.6). There was no evidence for cross-transmission of mania and MDEs (OR ¼ .7, CI:.5–1.1), psychosis and mania (OR ¼ 1.0, CI:.4–2.7) or psychosis and MDEs (OR ¼ 1.0, CI:.7–1.4). -
Social Psychoneuroimmunology: Understanding Bidirectional Links Between Social Experiences and the Immune System
Brain, Behavior, and Immunity xxx (xxxx) xxx Contents lists available at ScienceDirect Brain Behavior and Immunity journal homepage: www.elsevier.com/locate/ybrbi Viewpoint Social psychoneuroimmunology: Understanding bidirectional links between social experiences and the immune system Keely A. Muscatell University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Does the immune system have a “social life,” wherein our social have historically signaled) increased likelihood of injury (e.g., ostra experiences can affect and be affected by the activities of the immune cism) or infection (e.g., socially connecting with others) will lead to system? Research in the nascent subfield of social psychoneuroimmunol changes in the activities of the immune system (Kemeny, 2009; Eisen ogy suggests that the answer to this question is a resounding “yes” – there berger et al., 2017; Gassen and Hill, 2019; Slavich and Cole, 2013; are profound bidirectional connections between social experiences and Leschak and Eisenberger, 2019). The second core tenant is that the brain the immune system. Yet there are also vast opportunities for discovery in is constantly monitoring the physiological state of the body and inte this new subfield. In this article, I briefly define and outline some core grating this information with signals from the broader environment to tenants of social psychoneuroimmunology (Fig. 1). I also highlight op gauge metabolic demands and guide adaptive behavior (Sterling, 2012). portunities for future work in this area. Bringing together social psy As such, even relatively minor fluctuationsin immune system activation chological and psychoneuroimmunology research will undoubtedly lead outside of an experience of acute illness, injury, or chronic disease, can to important discoveries about the interconnections between the im feed back to the brain to guide social cognition and behavior. -
Living with Threats of Violence
Living with threats of violence People who are frequently exposed to violence or live with threats of violence may experience psychological, emotional, and physical effects. Whether the threat of violence is the result of living in a dangerous neighborhood or being involved in an abusive relationship, common reactions include fear, depression, anxiety, and post-traumatic stress disorder. These stress reactions are normal but can seriously interfere with everyday life and the ability to function at home, work, or school. Common reactions Coping with stress and anxiety If the threat of violence and conflict is constant Living with the threat of violence is an unfortunate and unpredictable, people may operate in “survival reality for many people around the world. Ways to mode” and find it difficult to focus on anything but manage stress and anxiety include the following: the looming threat. For most people, being physically • Take care of yourself first. Eat healthy foods, get threatened is a traumatic event. Emotional and enough rest, and exercise on a regular basis. physical responses to traumatic events may include: Physical activity can relieve anxiety and promote • Shock, confusion, and intense fear well-being. • Anxiety and sadness • Talk about your concerns with people you trust. A • Physical reactions such as headaches, supportive network is very important for emotional stomachaches, chest pains, racing pulse, dizzy health. spells, trouble sleeping and changes in appetite • Avoid excessive use of caffeine, alcohol and • Being easily startled nicotine. • Feelings of anger, guilt, despair, and self-blame • Balance work and play. Make time for hobbies and activities you enjoy, or find interesting volunteer • Difficulty concentrating work. -
Stress, Emotion Regulation, and Well-Being Among Canadian Faculty Members in Research-Intensive Universities
social sciences $€ £ ¥ Article Stress, Emotion Regulation, and Well-Being among Canadian Faculty Members in Research-Intensive Universities Raheleh Salimzadeh *, Nathan C. Hall and Alenoush Saroyan Department of Educational and Counselling Psychology, McGill University, Montreal, QC H3A 1Y2, Canada; [email protected] (N.C.H.); [email protected] (A.S.) * Correspondence: [email protected] Received: 22 September 2020; Accepted: 25 November 2020; Published: 10 December 2020 Abstract: Existing research reveals the academic profession to be stressful and emotion-laden. Recent evidence further shows job-related stress and emotion regulation to impact faculty well-being and productivity. The present study recruited 414 Canadian faculty members from 13 English-speaking research-intensive universities. We examined the associations between perceived stressors, emotion regulation strategies, including reappraisal, suppression, adaptive upregulation of positive emotions, maladaptive downregulation of positive emotions, as well as adaptive and maladaptive downregulation of negative emotions, and well-being outcomes (emotional exhaustion, job satisfaction, quitting intentions, psychological maladjustment, and illness symptoms). Additionally, the study explored the moderating role of stress, gender, and years of experience in the link between emotion regulation and well-being as well as the interactions between adaptive and maladaptive emotion regulation strategies in predicting well-being. The results revealed that cognitive reappraisal was a health-beneficial strategy, whereas suppression and maladaptive strategies for downregulating positive and negative emotions were detrimental. Strategies previously defined as adaptive for downregulating negative emotions and upregulating positive emotions did not significantly predict well-being. In contrast, strategies for downregulating negative emotions previously defined as dysfunctional showed the strongest maladaptive associations with ill health. -
Chapter 7 Mood Disorders
An Overview of Mood Disorders • Gross Deviations in Mood • 2 Fundamental states: Depression & Mania Chapter 7 • Depression: “The Low” – Major Depressive Episode •The most commonly diagnosed & most severe Mood Disorders depression •Depressed (or in children, irritable) mood state that lasts at least 2 weeks –Cognitive symptoms •Feelings of worthlessness or inappropriate guilt •Diminished ability to concentrate or indecisiveness – Dysthymic Disorder –Disturbed physical functions (vegetative •Similar symptoms to Major Depressive Episode, symptoms) (central to the disorder) but milder •Insomnia or hypersomnia nearly every day –Also fewer symptoms: need only 2 of the •Significant weight loss or gain or change in symptoms, as opposed to 5 in Major Depressive appetite Episode •Fatigue or loss of energy nearly every day •A persistently depressed (or, in children & •Psychomotor agitation or retardation adolescents, irritable) mood that continues for at –Nearly always accompanied by markedly least 2 years diminished interest or ability to experience pleasure –During those 2 years, the individual has never been (anhedonia) from life without the symptoms for more than 2 months at a • Average duration if untreated: 9 months time •Most people with Dysthymia eventually experience a major depressive episode • Mania: “The High” –Abnormally exaggerated elation, joy, or euphoria OR irritability (common toward the –Behavioral symptoms end of the episode) lasting at least 1 week •More talkative / pressured speech –Cognitive symptoms •Psychomotor agitation -
What Is Bipolar Disorder?
Bipolar Disorder Fact Sheet For more information about bipolar or other mental health disorders, call 513-563-HOPE or visit our website at www.lindnercenterofhope.com. What Is Bipolar Disorder? What does your mood Each year, nearly 6 million adults (or approximately 5% of the population) in the U.S. are affected by bipolar disorder, according to the Depression and Bipolar Support say about you? Alliance. While the condition is treatable, unfortunately bipolar disorder is frequently misdiagnosed and may be present an average of 10 years before it is correctly identified. Go to My Mood Monitor™, a three minute assessment Bipolar disorder (also known as bipolar depression or manic depression) is identified for anxiety, depression, PTSD by extreme shifts in mood, energy, and functioning that can be subtle or dramatic. The characteristics can vary greatly among individuals and even throughout the and bipolar disorder, at course of one individual’s life. www.mymoodmonitor.com to see if you may need a Bipolar disorder is usually a life-long condition that begins in adolescence or early professional evaluation. adulthood with recurring episodes of mania (highs) and depression (lows) that can continue for days, months or even years. My Mood Monitor™ Copyright © 2002-2010 by M3 Information™ Phases of Bipolar Disorder • Mania is the activated phase of bipolar disorder and is characterized by extreme moods, increased or impulsive mental and physical activities, and risk taking. • Hypomania describes a mild-to-moderate level of mania. Because it may feel good to the individual experiencing it, this condition can be difficult for someone with bipolar illness to recognize as a concern. -
Post-Traumatic Stress Disorder (PTSD) and Sleep
SHF-PTSD-0312 21/3/12 6:20 PM Page 1 Post-Traumatic Stress Disorder (PTSD) and Sleep Important Things to Know About PTSD and Sleep • PTSD can happen after a period of extreme trauma and stress. • One of the symptoms of PTSD may be problems with sleeping. • The treatment for this will depend on how the PTSD is affecting sleep. • There are many treatments available. How might PTSD affect sleep? • Insomnia. People with PTSD may have difficulty with getting to sleep or staying asleep. They may wake up There are may sleep problems that may be associated frequently during the night and be unable to get back with PTSD. For more information on the disorders to sleep. mentioned below see the relevant pages on this website. • Issues linked to the body clock, such as Delayed Sleep • The extreme anxiety of PTSD (caused by trauma or Phase Disorder may occur in a person with PTSD. If you catastrophe) can seriously disrupt sleep. In some cases can’t get to sleep until very late at night and then this starts a few months after the event. You might need to sleep in you may be experiencing this suffer from horror or strong fear and feel helpless. See problem. Anxiety and Sleep. • Obstructive Sleep Apnoea may be caused by weight • People with PTSD have higher rates of depression and gain due to the life style changes associated with the this is often associated with poor sleep. See PTSD. If the sleep apnoea is serious, medications such Depression and Sleep. as Seroquel can be an additional danger.